Mother Tincture
An alcoholic tincture of the whole flowering plant, used at traditional drop dosages.
Whole Plant · Liquid
French Pharmacopoeia · EMA Monograph
Biological Overview
California Poppy is an annual Papaveraceae native to California and the southwestern United States, widely cultivated as a garden ornamental, with finely cut blue-green foliage and solitary orange-yellow flowers that close at night. Its colorless latex and pavine alkaloid content underlie its long use as a gentle, non-addictive sedative.
Life CycleAnnual
HabitatCalifornia, SW USA
Alkaloid Content0.5–1.2% (pavines)
ToxicityAtoxic (LD50 >10 g/kg)
Botanical Classification
Taxonomy & Identification
- Latin Name
- Eschscholzia californica Cham.
- Common Spelling
- Eschscholtzia californica
- Family
- Papaveraceae
- Common Names
- California Poppy, Golden Poppy
- Parts Used
- Flowering aerial parts
- Habitat
- California & southwestern United States
- Marker Compound
- Californidine
Ethnobotany & Traditional Use
History & Tradition
Native American peoples used the plant's latex as an analgesic for toothache and colic, long before its pharmacology was studied.
The genus is named for the Baltic German botanist Johann Friedrich von Eschscholtz, honored by his colleague Adelbert von Chamisso during a 19th-century round-the-world expedition that passed along the California coast.
European pharmacological interest grew through the late 20th century, culminating in formal listing in the French Pharmacopoeia and a European Medicines Agency herbal monograph.
⚠ Spelling Note
The genus is properly spelled Eschscholzia (no "t"), though Eschscholtzia is the common — and pharmacopoeia-recognized — variant used throughout the herbal trade and on most product labels.
The Key Molecule
Californidine — Deep Dive
The principal pavine-type alkaloid in California poppy, and the official marker compound used to standardize the plant.
🧠
🔬
Serotonergic Receptor Binding
Certain alkaloids inhibit binding to 5-HT1A receptors in vitro, suggesting a serotonergic contribution to the plant's mood-related effects.[16]
🧬
Cholinesterase Inhibition
Related benzylisoquinoline alkaloids (reticuline) inhibit acetylcholinesterase and butyrylcholinesterase.[17]
📏
Regulatory Standardization
Californidine content is the official marker the French Pharmacopoeia uses to standardize total alkaloid content (0.5–1.2%) in the flowering aerial parts.
⚠ Standardization Matters
Extract type affects drug-interaction risk.
A plain aqueous extract (tea) and californidine alone did not affect cytochrome P450 enzymes in one study, while concentrated alcoholic/dry extracts showed meaningful CYP inhibition. Look for products that specify both the extract type and californidine standardization.[25]
Pharmaceutical Preparations
Parts Used & Available Forms
Only the flowering aerial parts of California poppy are used medicinally, occasionally with the root.
Dry Extract
Aqueous or hydroalcoholic dry extracts, generally standardized to californidine content.
Aqueous · Hydroalcoholic
Powder & EPS
Dried powdered herb, or a standardized fresh-plant extract (EPS), for capsule and tablet formats.
Powder · Fresh Plant
Clinical Dosimetry
Dosages
Per the European Medicines Agency's herbal monograph on Eschscholzia californica.
Phytochemistry
Composition
California poppy's chemistry centers on a diverse mixture of pavine and isoquinoline alkaloids (0.5–1.2%), alongside flavonoids and phytosterols.[1]
Pavine & Isoquinoline Alkaloids (0.5–1.2%)
CalifornidineOfficial marker alkaloid for standardization
Major
EschscholtzineCharacteristic major pavine alkaloid
Major
Protopine (Fumarine)Shared with other Papaveraceae; GABA-ergic
Present
Sanguinarine & ChelerythrineBenzophenanthridines, concentrated in roots; detoxified in planta by sanguinarine reductase[23]
Present
AporphinesGlaucine, magnoflorine, larotetamine
Trace
Berberine & CoptisineProtoberberine-class alkaloids
Trace
Other Constituents
Isoflavones2'-methoxyformononetin and related compounds
Present
Phytosterols & CarotenoidsGeneral phytochemical background constituents
Present
LinamarineCyanogenic glycoside, minor quantity
Trace
😌
Spasmolytic & Sedative
Demonstrated spasmolytic and sedative activity, including in combination with Corydalis cava (80:20 ratio).[4][5][6][7]
🕊️
Anxiolytic
Confirmed in a 264-patient RCT for mild-to-moderate generalized anxiety; effect described as dose-dependent — anxiolytic at low dose, sedative at higher dose.[8][9][19]
😴
Hypnotic & Sleep-Inducing
Reduces sleep latency and prolongs sleep duration in animal models.[13][14]
💊
Analgesic (Opioid-Related)
Acts on enkephalins, endorphins, and opioid receptors of the nociceptive system; recommended in pediatric use for minor pain.[10][11][21]
🧠
GABA-ergic (Benzodiazepine-like)
Protopine-type alkaloids enhance GABA receptor binding, a benzodiazepine-like mechanism.[12]
🔬
Serotonergic
Select alkaloids bind 5-HT1A serotonin receptors in vitro.[16]
🧬
Acetyl/Butyrylcholinesterase Inhibitor
Benzylisoquinoline alkaloids, including reticuline, inhibit acetylcholinesterase and butyrylcholinesterase.[17]
💧
Vasopressin V1 Receptor Affinity
Benzophenanthridines (sanguinarine, chelerythrine) show affinity for hepatic vasopressin V1 receptors.[18]
⚗️
Catecholamine Metabolism Modulation
Inhibits enzymatic degradation of catecholamines, a mechanism linked to the plant's hypnotic effects.[15]
🛡️
Antifungal
Isoquinoline alkaloids active against Alternaria, Curvularia, Helminthosporium, and Fusarium species.[22]
Animal Pharmacology — Dose-Response Data
- •Anxiolytic effect at 25 mg/kg of dried plant — comparable to the reference benzodiazepine chlorazepate at 1–5 mg/kg.
- •Sedative effect at 100–400 mg/kg — comparable to chlorazepate at 5–10 mg/kg.
- •Sleep-inducing effect from 100 mg/kg — comparable to a chlorazepate reference dose of 10 mg/kg.
- •Minor analgesic effect from 200 mg/kg — comparable to acetylsalicylic acid at 68 mg/kg.
Per a pharmacological synthesis by Fleurentin: these traditional indications are broadly confirmed by animal experimentation, though the specific active principle(s) responsible have not been identified with certainty in the scientific literature; in vivo and in vitro testing suggests unidentified extract components may act on the GABA-ergic complex.[24]
Clinical Applications
Clinical Indications
Traditional and clinically studied applications drawn from the primary literature.
😴
Sleep & Insomnia
Onset & Maintenance
🕊️
Anxiety & Nervous Tension
Mild-to-Moderate
- Generalized anxiety: mild-to-moderate intensity, studied in combination with hawthorn and magnesium. [9]
- Headaches: documented traditional indication.
🧒
Pediatric Applications
Nervous Complaints
- Childhood neuropathies & nocturnal enuresis: traditionally combined with oat (Avena).
- Use under age 6: should be avoided due to alkaloid content (see Safety).
Pharmacodynamics
Mode of Action
Documented mechanisms underlying California poppy's sedative, anxiolytic, and analgesic effects.
🧠
🔬
⚗️
🚫
Documented Absence of Other CNS Effects
Animal pharmacology studies found no neuroleptic, antidepressant, antihistaminic, myorelaxant, or antiepileptic activity — distinguishing the plant's mechanism from broader-spectrum sedative herbs.[24]
Clinical Safety
Safety, Interactions & Precautions
Generally well tolerated, but California poppy's alkaloid content requires attention to specific contraindications.
Adverse Effects & Cautions
- Atoxic profile: no mortality in mice at 5 g/kg intraperitoneal; no adverse reactions in rats at oral doses up to 2 g/kg. [24]
- Glaucoma: contraindicated due to sanguinarine content.
- Pregnancy & young children: avoid in pregnancy and in children under 6 years due to alkaloid content.
- Combination products: a pharmacovigilance case report described hallucinations and confusion in a 93-year-old patient taking a sleep supplement combining melatonin and California poppy.
Drug Interactions
- CYP3A4, CYP2C9, CYP2C19: strongly inhibited by escholtzine and allocryptopine in concentrated extracts. [25]
- CYP2D6: reversibly inhibited by protopine and allocryptopine. [25]
- Extract type matters: a plain aqueous extract (tea) and californidine alone did not affect cytochrome P450 enzymes, P-glycoprotein, or the pregnane X receptor in the same study — interaction risk appears concentrated in stronger extracts. [25]
Clinical Disclaimer: This monograph is for educational and professional reference only. It does not constitute medical advice, diagnosis, or treatment guidance. Always consult a qualified healthcare provider before initiating any phytotherapeutic regimen, particularly if you are taking prescription medications, are pregnant, have glaucoma, or have existing health conditions.
Common Questions
Frequently Asked Questions
What is California poppy used for?
California poppy (Eschscholzia californica) is used for insomnia and difficulty falling asleep, mild-to-moderate generalized anxiety, headaches, minor pain, and pediatric nervous complaints such as nocturnal enuresis.
Is California poppy addictive?
No. Animal studies found it to be atoxic, with no mortality at high doses and no evidence of the dependence patterns associated with opioid-derived poppy relatives.
What is the difference between California poppy and opium poppy?
They are different genera. California poppy (Eschscholzia californica) does not contain morphine or codeine and is not a narcotic; its activity comes from pavine and protopine-type alkaloids acting on GABA and serotonin receptors, not opioid receptors directly.
What is the recommended dosage of California poppy?
The European Medicines Agency's herbal monograph cites a recommended daily dose of 960 to 1500 mg of powder or equivalent galenic forms. Always confirm dosing with a qualified healthcare provider.
Is California poppy safe during pregnancy?
No. It should be avoided during pregnancy and in children under 6 years of age due to its alkaloid content.
Does California poppy interact with medications?
Concentrated extracts can strongly inhibit CYP3A4, CYP2C9, and CYP2C19, and reversibly inhibit CYP2D6. Notably, a plain aqueous extract (tea) and its main alkaloid, californidine, did not affect these cytochromes, P-glycoprotein, or the pregnane X receptor in the same study — meaning interaction risk appears tied to the extract type.
Can California poppy be combined with melatonin?
Use caution. A pharmacovigilance case report described hallucinations and confusion in a 93-year-old patient taking a sleep supplement that combined melatonin and California poppy.
Is California poppy safe for people with glaucoma?
No. It is contraindicated in glaucoma due to its sanguinarine content.
What is californidine?
Californidine is the principal pavine-type alkaloid in California poppy and the official marker compound used by the French Pharmacopoeia to standardize the plant's total alkaloid content.
Can children use California poppy?
It should be avoided in children under 6. In older children, it has a traditional use for nervous complaints and nocturnal enuresis, often combined with oat (Avena), but should only be used under professional guidance.
Primary Literature
Bibliography
↑
1.
Jain L, Tripathi M, Pandey VB. Alkaloids of Eschscholtzia californica. Planta Med. 1996;62(2):188.
PubMed PMID:17252440 →
↑
2.
Beck MA, Häberlein H. Flavonol glycosides from Eschscholtzia californica. Phytochemistry. 1999;50(2):329-332.
PubMed PMID:9933948 →
↑
3.
Jain L, Tripathi M, Pandey VB, Rücker G. Flavonoids from Eschscholtzia californica. Phytochemistry. 1996;41(2):661-662.
DOI:10.1016/0031-9422(95)00561-7 →
↑
4.
Vincieri FF, Celli S, Mulinacci N, Speroni E. An approach to the study of the biological activity of Eschscholtzia californica Cham. Pharmacol Res Commun. 1988;20(Suppl 5):41-44.
PubMed PMID:3247350 →
↑
5.
Hennebelle T, Sahpaz S, Bailleul F. Plantes sédatives: évaluation pharmacologique et clinique. Médecine du Sommeil. 2007;4(13):4-14.
↑
6.
Schulz H, Jobert M, Hübner WD. The quantitative EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepam. Phytomedicine. 1998;5(6):449-458.
PubMed PMID:23196028 →
↑
7.
Schäfer HL, Schäfer H, Schneider W, Elstner EF. Sedative action of extract combinations of Eschscholtzia californica and Corydalis cava. Arzneimittelforschung. 1995;45(2):124-126.
PubMed PMID:7710431 →
↑
8.
Abascal K, Yarnell E. Nervine herbs for treating anxiety. Altern Complement Ther. 2004;Dec:309-315.
Full text →
↑
9.
Hanus M, Lafon J, Mathieu M. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin. 2004;20(1):63-71.
DOI:10.1185/030079903125002603 →
↑
10.
Soulimani R. Recherche et évaluation de l'activité biologique des substances végétales sur le SNC chez la souris, in vivo et vis-à-vis des récepteurs cholinergiques, histaminergiques et opioïdes, in vitro. Doctoral thesis, Université Paul Verlaine-Metz; 1992.
↑
11.
Reimeier C, Schneider I, Schneider W, Schäfer HL, Elstner EF. Effects of ethanolic extracts from Eschscholtzia californica and Corydalis cava on dimerization and oxidation of enkephalins. Arzneimittelforschung. 1995;45(2):132-136.
PubMed PMID:7710433 →
↑
12.
Kardos J, Blaskó G, Simonyi M. Enhancement of gamma-aminobutyric acid receptor binding by protopine-type alkaloids. Arzneimittelforschung. 1986;36(6):939-940.
PubMed PMID:3017370 →
↑
13.
Rolland A, Fleurentin J, Lanhers MC, Younos C, Misslin R, Mortier F, Pelt JM. Behavioural effects of the American traditional plant Eschscholzia californica: sedative and anxiolytic properties. Planta Med. 1991;57(3):212-216.
PubMed PMID:1680240 →
↑
14.
Gomis Devesa AJ, Martínez AM, Ortega-Albás JJ. Herbal drugs and sleep: what can we expect? J Sleep Disord Ther. 2015;4:196.
DOI:10.4172/2167-0277.1000196 →
↑
15.
Kleber E, Schneider W, Schäfer HL, Elstner EF. Modulation of key reactions of the catecholamine metabolism by extracts from Eschscholtzia californica and Corydalis cava. Arzneimittelforschung. 1995;45(2):127-131.
PubMed PMID:7710432 →
↑
16.
Gafner S, Dietz BM, McPhail KL, et al. Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in vitro. J Nat Prod. 2006;69(3):432-435.
PubMed PMID:16562853 →
↑
17.
Cahlíková L, Macáková K, Kuneš J, Kurfürst M, Opletal L, Cvačka J, Chlebek J, Blunden G. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Eschscholzia californica (Papaveraceae). Nat Prod Commun. 2010;5(7):1035-1038.
PubMed PMID:20734935 →
↑
18.
Granger I, Serradeil-le Gal C, Augereau JM, Gleye J. Benzophenanthridine alkaloids isolated from Eschscholtzia californica cell suspension cultures interact with vasopressin (V1) receptors. Planta Med. 1992;58(1):35-38.
PubMed PMID:1535715 →
↑
19.
Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J. 2010;9:42.
Full text (PMC2959081) →
↑
20.
Fedurco M, Gregorová J, Šebrlová K, et al. Modulatory effects of Eschscholzia californica alkaloids on recombinant GABAA receptors. Biochem Res Int. 2015;2015:617620.
PubMed PMID:26509084 →
↑
21.
Rolland A, Fleurentin J, Lanhers MC, Misslin R, Mortier F. Neurophysiological effects of an extract of Eschscholzia californica Cham. (Papaveraceae). Phytother Res. 2001;15(5):377-381.
PubMed PMID:11507727 →
↑
22.
Singh S, Jain L, Pandey MB, Singh UP, Pandey VB. Antifungal activity of the alkaloids from Eschscholzia californica. Folia Microbiol (Praha). 2009;54(3):204-206.
PubMed PMID:19649736 →
↑
23.
Vogel M, Lawson M, Sippl W, Conrad U, Roos W. Structure and mechanism of sanguinarine reductase, an enzyme of alkaloid detoxification. J Biol Chem. 2010;285(24):18397-18406.
PubMed PMID:20378534 →
↑
24.
Fleurentin J, Mortier F, Younos C. Eschscholtzia, Eschscholtzia californica Cham. Papaveraceae. In: Cornillot P, ed. Encyclopédie des médecines naturelles. Frison-Roche; 1996.
↑
25.
Manda VK, Ibrahim MA, Dale OR, et al. Modulation of CYPs, P-gp, and PXR by Eschscholzia californica (California Poppy) and its alkaloids. Planta Med. 2016;82(6):551-558.
PubMed PMID:27054913 →
Additional Reference Literature
Ghedira K, Goetz P, Le Jeune R. Pavot jaune de Californie Eschschol(t)zia californica Cham. (Papaveraceae). Phytothérapie. 2010;8(4):249-254.
Paul LD, Springer D, Staack RF, Kraemer T, Maurer HH. Cytochrome P450 isoenzymes involved in rat liver microsomal metabolism of californine and protopine. Eur J Pharmacol. 2004;485(1-3):69-79. PubMed PMID:14757125 →
Ikezawa N, Iwasa K, Sato F. CYP719A subfamily of cytochrome P450 oxygenases and isoquinoline alkaloid biosynthesis in Eschscholzia californica. Plant Cell Rep. 2009;28(1):123-133. PubMed PMID:18854999 →
Bruneton J. Pharmacognosie, Phytochimie, Plantes médicinales. Tec & Doc. 1997:745.
Fleurentin J. Les Plantes qui nous soignent. Ouest France. 2007.
ANSES. Vigil'Anses: hallucinations and confusion associated with a melatonin/California poppy sleep supplement in a 93-year-old patient. 2024. Full report →